Manipulation of the growth rate of human breast cancer cells by antiandrogen followed by chemotherapy

• Published in: Anticancer research Vol. 10; no. 3; p. 853
• Main Authors: Alama, A, Miglietta, L, Favoni, R E, Barbieri, F, Ravera, F, Fazzuoli, L, Nicolo, G, Nicolin, A
• Format: Journal Article
• Language: English
• Published: Greece 01.05.1990
• Subjects: Androgen Antagonists - pharmacology; Antineoplastic Agents - pharmacology; Breast Neoplasms; Cell Cycle - drug effects; Cell Division - drug effects; Cell Line; Cell Nucleus - metabolism; Cyproterone - analogs & derivatives; Cyproterone - pharmacology; Cyproterone Acetate; Cytosol - metabolism; DNA, Neoplasm - drug effects; DNA, Neoplasm - metabolism; Doxorubicin - pharmacology; Drug Synergism; Female; Humans; Methotrexate - pharmacology; Receptors, Androgen - metabolism; Receptors, Estrogen - metabolism; Receptors, Progesterone - metabolism; Receptors, Steroid - drug effects; Receptors, Steroid - metabolism; Tumor Cells, Cultured - cytology; Tumor Cells, Cultured - drug effects
• ISSN: 0250-7005

The effects induced by the antiandrogen Cyproterone Acetate (CPA) on the proliferation of EVSA-T human breast cancer cells endowed with androgen receptors were studied. Kinetic analyses were carried out by two autoradiographic techniques measuring the percentage of cells in S-phase and the growth fraction (GF). The exposure of the cultures to CPA for 24 h caused a marked inhibition on S-phase cells without significantly affecting the CF. The accumulation of cells in G1-phase, confirmed by cytometric analysis, was rescued to the S compartment by replacing the culture medium 24 h after CPA administration. Exposure of EVSA-T to Doxorubicin or Methotrexate after CPA and medium change at the time of maximal proliferative recruitment, led to an enhancement of cytotoxicity as demonstrated by colony survival assay.